Lynx1 Capital Management LP has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $279 Million distributed in 18 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Merus N.V. with a value of $89.6M, Stoke Therapeutics, Inc. with a value of $63.8M, C4 Therapeutics, Inc. with a value of $39.2M, Gh Research PLC with a value of $28.1M, and T Scan Therapeutics, Inc. with a value of $26M.

Examining the 13F form we can see an decrease of $987M in the current position value, from $1.27B to 279M.

Lynx1 Capital Management LP is based out at San Juan, PR

Below you can find more details about Lynx1 Capital Management LP portfolio as well as his latest detailed transactions.

Portfolio value $279 Million
Healthcare: $279 Million

Stock Holdings Table Market Cap. of $2 Billions to $10 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 18
  • Current Value $279 Million
  • Prior Value $1.27 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 17 stocks
  • Additional Purchases 1 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 0 stocks
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.